Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer.

EJNMMI research·2026
Same author

Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.

NMR in biomedicine·2026
Same author

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Fractionation gives therapeutic benefit in animal model of [<sup>177</sup>Lu]Lu-PSMA-617 therapy of prostate cancer.

EJNMMI research·2026
Same author

Prognostic value of tumour volume based on [<sup>18</sup>F]PSMA-1007 PET/CT in prostate cancer.

EJNMMI reports·2026
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities.

Susan Evans-Axelsson1, Oskar Vilhelmsson Timmermand2, Anders Bjartell3

  • 1Department of Translational Medicine, Division of Urological Cancers, Skåne University Hospital, Malmö, Lund University, Lund, Sweden.

Seminars in Nuclear Medicine
|February 22, 2016
PubMed
Summary
This summary is machine-generated.

Radioimmunotherapy (RIT) offers a promising targeted approach for prostate cancer (PCa) treatment. Ongoing research focuses on improving RIT strategies and dosimetry for better efficacy and patient survival.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Related Experiment Videos

Last Updated: Mar 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate cancer (PCa) is a leading cause of cancer-related deaths in men globally.
  • Current therapies have limitations, necessitating the development of improved treatment modalities.
  • Targeted therapies, such as radioimmunotherapy (RIT), show promise for enhancing therapeutic efficacy.

Purpose of the Study:

  • To review the current landscape of RIT for prostate cancer.
  • To highlight the need for standardized dosimetry data in RIT studies.
  • To discuss advancements in RIT targets, strategies, and radionuclide candidates for PCa.

Main Methods:

  • Review of preclinical and clinical studies on RIT for PCa.
  • Analysis of emerging targeting strategies, including combination and pretargeting RIT.
  • Evaluation of various therapeutic radionuclide candidates.

Main Results:

  • RIT demonstrates potential as a targeted therapy for PCa.
  • A lack of consistent dosimetry data hinders inter-study comparisons.
  • Improved RIT strategies and tools are enhancing clinical responses.

Conclusions:

  • RIT is an evolving and increasingly practical clinical tool for prostate cancer.
  • Further research into dosimetry and novel RIT approaches is crucial.
  • Combination therapies and advanced targeting strategies are key to maximizing RIT's potential in PCa treatment.